Bob Holmen, J.D., has over 25 years of experience working in and advising technology, healthcare, and financial services companies. He has engaged at every phase of corporate development, from formation to financing to operations to exiting, and has served in diverse roles from electrical engineer (Hughes Aircraft) to an associate at major law firms (Latham & Watkins, Morrison & Foerster), to general counsel for a series of technology and financial services companies, to co-founder and managing director for a family of venture funds (Miramar Venture Partners). Currently, Mr. Holmen provides legal services to investors through his boutique law firm Investor Counsel, focused on the venture capital and private equity markets. His work encompasses fund formation, financing and operations, structuring, and negotiating investments, mergers and acquisition, and purchaser representation. In addition, he continues to serve as a Managing Director for the legacy (fully invested) Miramar Venture Partners funds. Mr. Holmen also has served as an adjunct professor, teaching “Venture Capital Law” at the UC Irvine Law School and “Investing in New Ventures” at USC’s Marshall School of Business, in addition to writing about venture and M&A matters. He received his B.S. in electrical engineering from Stanford University and his J.D. from UC Berkeley School of Law.

Phillip Donenberg brings more than 25 years of leadership expertise in finance, mergers and acquisitions and operations focused in the life sciences, biotech and pharmaceutical industries. He currently serves as Board Director and Audit Chairman of Taysha Gene Therapies and Tectonic Therapeutic, Inc. His background includes recent experience with a gene therapy company, AveXis, Inc., where he served as the Chief Financial Officer and Senior Vice President until July 2018, through its $8.7 billion acquisition by Novartis.

Phillip has held leadership roles overseeing strategic transactions, finance management and accounting operations, controls and reporting processes for growing life sciences companies in the Chicago area. Most recently, he was Chief Financial Officer and Senior Vice President of Jaguar Gene Therapy, LLC. Phillip earned a bachelor’s degree in accountancy from the University of Illinois, and he is a Certified Public Accountant.

Christopher Gerry, J.D., is a life sciences attorney with experience in operations, business development and strategy. Prior to joining Sensei in July 2022, Mr. Gerry served as VP, Deputy General Counsel at AVROBIO, where he was responsible for SEC reporting and public company affairs, financings, corporate governance, business development and various other legal matters. Previously, Mr. Gerry was an associate at Cooley LLP, where he represented life sciences companies in a wide variety of matters through all stages of their life cycle, from initial formation through venture financings, initial public offerings, follow-on offerings and exit events. He holds a B.A. from Dickinson College and earned his J.D. from Boston University School of Law.

Kristian Humer, MBA, was appointed to Sensei’s board of directors in August 2021. Mr. Humer spent 20 years on Wall Street, including 14 years as a life science-focused investment banker. Most recently Kristian served as chief financial officer and chief business officer at Viridian Therapeutics (NASDAQ: VRDN) beginning in July 2021. Previously, he spent 11 years with Citigroup, Inc., most recently as managing director, where he helped lead the firm’s investment banking engagements for small and mid-sized biopharma and select large cap pharmaceutical companies. Prior to joining Citigroup, Inc., Mr. Humer served as vice president of the Investment Banking Division for the Global Healthcare Group team at Lehman Brothers, Inc. Mr. Humer started his career serving positions of increasing responsibility in the investment banking and private banking divisions of UBS AG and Merrill Lynch (a Bank of America company). He received an MBA from the Fuqua School of Business at Duke University and a B.A. with honors in accounting and economics from the University of Reading, United Kingdom.

Anand Parikh is the Co-Founder of Faeth Therapeutics.  Prior to co-founding Faeth, Mr. Parikh served in multiple executive roles at Virta Health, including General Counsel, Head of Finance and Head of Human Resources. In these roles, he was responsible for legal, finance, human resources, and corporate operations functions and supported the company’s growth and strategic initiatives.

Earlier in his career, Mr. Parikh was a Corporate Associate at Morrison & Foerster LLP, where he advised emerging growth companies and investors on corporate transactions, including financings and mergers and acquisitions.

Mr. Parikh holds a J.D. from New York University School of Law and a B.A. in Political Science from the University of Michigan.

Tom Ricks, MBA, has been a member of the Board of Directors since 2015. Mr. Ricks is the former chief investment officer of H&S Ventures LLC, a private investment firm. Prior to taking this position with H&S Ventures, he was chief executive officer of The University of Texas Investment Management Company. Mr. Ricks also served as vice chancellor for asset management for The University of Texas System and as executive director of finance and private investments. He has been a director of Newfield Exploration Company (NYSE:NFX) since 1992 and is chairman of its Audit Committee. He is a former director of BDM International, DTM Corporation, LifeCell Corporation, and Argus Pharmaceuticals. Mr. Ricks also previously served on the Investment Committee of the University of California Foundation, Irvine, and previously served on the board of the Ocean Institute. Mr. Ricks holds a B.A. in economics from Trinity College, and an MBA from the University of Chicago.